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Background
Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic
hematopoietic stem cell transplantation. Results were derived from heterogeneous, small pop-
ulations and their value remains a matter of debate. 
Design and Methods
In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin
1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), inter-
feron (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor
receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a
homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia.
Three good predictors of overall survival, identified via statistical methods including Cox
regression analysis, were investigated for their effects on transplant-related mortality and
relapse. Predictive power was assessed after integration into the established European Group
for Blood and Marrow Transplantation (EBMT) risk score.
Results
Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor
IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and
decreased survival. Application of prediction error and concordance index statistics gave evi-
dence that integration improved the EBMT risk score.
Conclusions
Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell
transplantation. When three genetic polymorphisms were added into the EBMT risk model
they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve
donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell
transplantation. 
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Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the main curative therapy for many congenital
or acquired disorders of the hematopoietic system but is
still associated with substantial morbidity and mortality.1,2
The main clinical factors influencing outcome after HSCT
have been determined through analyses of patients under-
going HSCT for chronic myeloid leukemia (CML).
Patients’ age, stage of the disease, time interval from diag-
nosis to transplant, histocompatibility and donor and
patient gender combination have been identified as key
pre-transplant risk factors in the European Group for
Blood and Marrow Transplantation (EBMT) clinical risk
score3 for all patients undergoing HSCT for a hematologic
disorder.4 Furthermore, a comorbidity score has been
introduced as a major additional co-factor for transplant-
related mortality.5 Recognition of these factors has led to
different decision algorithms and transplant procedures
for patients with high-risk disease and low-risk donors or
patients with low-risk disease and high-risk donors. In
parallel, major progress has been made in the drug treat-
ment of CML, although the best time point for HSCT
remains open because of second-generation tyrosine
kinase inhibitors.6-8 Even better characterization of the pre-
transplant risk profile is, therefore, urgently warranted.
In the last decade several groups, including ours, have
demonstrated that polymorphisms of non-HLA genes for
components of the innate immune system, pro- and anti-
inflammatory cytokines and steroid receptors are predic-
tive of outcome following HSCT.9
These results were derived from small series and were
not adjusted in a standardized format for the key risk
factors for HSCT outcome. We, therefore, investigated
the role of non-HLA genetics in a homogenous cohort of
CML patients who underwent transplantation from
HLA-matched sibling donors and, using the information
collected, derived a novel statistical model that inte-
grates genetics into the EBMT clinical risk score.
Design and Methods 
Study design
The final study population consisted of 228 HLA-matched sibling
adult patient and donor pairs (Table 1) collected prospectively with
complete clinical and genotyping data from ten European transplant
centers. All clinical data were collected from the EBMT database
ProMIse. At the last date of contact, 37% of patients had died and
24% had relapsed. The majority of patients were in first chronic phase
CML (80.3%), 12.3% were in accelerated phase, 4.8% were in second
chronic phase and 2.6% were in blast crisis at the time of transplanta-
tion. Transplants were conducted between April 1984 and September
2003, all in the pre-imatinib era. HLA genotype was determined by
standard technologies using serology or molecular typing and all
patients and donors were HLA-matched siblings. All except one
patient received standard bone marrow myeloablative conditioning.
All patients received standard supportive care which was comparative
across centers. The median survival time for those patients who were
alive at last contact was 54 months. The median survival time for the
patients who had died was 4.5 months. The main causes of death
were infection (39%), graft-versus-host disease (GVHD) (24%) and
relapse (22%); other causes of death included acute respiratory distress
syndrome and veno-occlusive disease. Clinical relapse was defined as
hematologic, cytogenetic or molecular relapse.10
All patients and donors gave informed consent to participation in
the study in accordance with EBMT guidelines. The protocol was
approved by the Local Research Ethics Committee at the coordinating
center (Newcastle upon Tyne, UK).
Genotyping for cytokine gene polymorphisms
DNA from the patients and donors was analyzed at a single coor-
dination center (Newcastle University, UK) for single nucleotide
polymorphisms (SNP) or microsatellites. The SNP or microsatellites
investigated included those in genes for cytokines or cytokine recep-
tors – interleukin 1 receptor antagonist (IL1RN),11 interleukin 4 (IL4),12
interleukin 6 (IL6),13 interleukin 10 (IL10),14 interferon (IFNG),15 tumor
necrosis factor (TNF),16 and tumor necrosis factor receptor II (TNFRS-
FIB),17 – and the steroid hormone receptors vitamin D receptor
(VDR)18 and estrogen receptor alpha (ESR1).19
The IL10 SNP, IL10-1082 and IL10-592 were recorded as haplotypes as
previously described.20
Statistical analysis
The impact of selected non-HLA genetic factors on survival, trans-
plant-related mortality and relapse was assessed. The methods used
included Kaplan-Meier estimates, Cox regression modeling and com-
peting risks analysis.21 The predictive accuracy of the models was
quantified using the concordance (c) index22 and prediction error (i.e.
0.632+ bootstrap estimator23). NCSS,24 R (version 2.6.2) and SPSS-14
were used for the computations. 
Results
Analysis of factors 
After initial univariable analysis, ten genetic variables
were identified as being associated with survival. These
variables were entered into a variable selection Cox
regression modeling procedure alongside the EBMT risk
score.25-27 The EBMT risk score was entered into the model
on an ordinal scale after initial testing for linearity.28
Three genetic variables (Table 2) remained significantly
associated with survival together with the EBMT risk
score. Absence in the donor of the IL10 ATA/ACC geno-
type* (N=200, 87.7%) (HR 0.43, 95% confidence interval:
0.17-1.07), presence in the donor of the IL1RN allele 2
genotype (N=45, 19.7%) (HR 2.45, 95% confidence inter-
val: 1.48-4.05 ) and absence in the patient of the TNFRS-
FIB 196R genotype (N=125, 54.8%) (HR 0.55, 95% confi-
dence interval: 0.35-0.87) decreased survival time – this is
further illustrated in Online Supplementary Figure S1. The
EBMT risk score remained significant for survival in the
final model with a hazard ratio of 1.67 (95% confidence
interval: 1.38-2.02). 
The decrease in survival was primarily due to an
increase in transplant-related mortality (Online Suppl -
ementary Table S1). The three genetic predictors had no
impact on relapse as indicated by Gray’s test.30
*After stepwise selection, donor IL10 ATA/ACC has a P value of 0.07 in
the model – this variable was still found to significantly improve the model
when all variables in the final model were assessed via hierarchical likeliho-
od ratio tests (level of significance 0.05).29
Validity testing of the selected genetic variables
The high-risk group was defined as patients with all
three adverse genetic polymorphisms (N=25). The low-
risk group comprised all remaining patients. Survival prob-
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ability was lower and incidence of transplant-related mor-
tality was higher for the high-risk group (Figure 1). As the
EBMT score increased, survival probability decreased and
transplant-related mortality incidence increased (Online
Supplementary Figure S2 A-B). It was also found that having
just one or two of the adverse genotypes conferred an
increased risk (hazard) of transplant-related mortality and
death as compared to the EBMT score alone (Online
Supplementary Table S2). This suggested an additive gene
dosage effect. 
After rounding and scaling Cox regression model coeffi-
cients, the genotypes were scored as 1 or 0 depending on
whether their presence or absence was detrimental to
transplant outcome i.e. absence of IL10 ATA/ACC geno-
type in the donor was scored 1 while its presence was
scored 0; presence of IL1RN allele 2 genotype in the donor
was scored 1 and its absence was scored 0; absence of
TNFRSFIB-196R genotype in the recipient was scored 1
and its presence was scored 0. This approach enabled up
to three score points to be added to the original EBMT
score. The resulting scores ranged from 0 to 8. No patients
scored “9” i.e. none of the patients whose EBMT score
was 6 had all three unfavorable genotypes.
The likelihood ratio test indicated that the genetic pre-
dictors, when viewed in addition to the EBMT risk score,
improved the goodness of fit (P<0.0005). 
Predictive value was quantified using the concordance
index22 and prediction error curves23 for (i) a model with
the single EBMT risk score variable and (ii) a model con-
taining the single EBMT risk score and the three geno-
types. The latter always appeared superior. Further details
of these statistical analyses are provided in the Online
Supplementary Appendix.
Discussion 
In this study we screened DNA from patients and
donors for SNP or microsatellites including those associat-
ed with cytokine genes transcribing high or low levels of
cytokines and/or inhibitors. Three genotypes were
demonstrated to be associated with impaired survival,
IL10 ATA/ACC (absence in the donor genotype), ILIRN
(allele 2) (presence in the donor genotype) and TNFRSFIB
196R (absence in the patient genotype). For all three geno-
types, survival was reduced due to increased transplant-
related mortality and their effects were additive with
worst survival in the group of 25 patients with all three
unfavorable genotypes. These genotypes had no effect on
relapse. 
These data fit with previous observations and explain
some discrepancies. Tumor necrosis factor (TNF) receptor
II, interleukin 10 (IL-10) and interleukin 1 (IL-1) all play a
role in modulating the “cytokine storm” of GVHD.
Absence of the TNFRSFIB allele R in the patient is indica-
A. Dickinson et al.
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Table 1. Patients’ characteristics: clinical factors.
High Risk Genotype Group1 Low Risk Genotype Group1 Total P value (2 sided tests)§
Frequency % (of 228) Frequency % (of 228) Frequency (%)
Patients’ gender 
Female 13 5.70 75 32.89 88 (38.6) 0.19*
Male 12 5.26 128 56.14 140 (61.4)
Stage of disease at transplantation
First chronic phase 20 8.77 163 71.49 183 (80.3) 1.00†
First accelerated phase 3 1.32 25 10.96 28 (12.3)
Higher chronic phase or blast crisis 2 0.88 15 6.58 17 (7.5)
Female donor to male patient 
Yes 5 2.19 60 26.32 65 (28.5) 0.36†
No 20 8.77 143 62.72 163 (71.5)
Patients’ age at transplantation 
Median age 38 38 0.63‡
Range 16-59 17-60
Patients’ age at transplantation 
16-19 years 1 0.44 6 2.63 7 (3.1) 1.00†
20-40 years 14 6.14 115 50.44 129 (56.6)
Greater than 40 years 10 4.39 82 35.96 92 (40.4)
Time from diagnosis to transplant 
12 months 17 7.46 134 58.77 151 (66.2) 1.00†
More than 12 months 8 3.51 69 30.26 77 (33.8)
Year of HSCT 
1984-1997 13 5.70 117 51.32 130 (57.0) 0.67†
1998-2003 12 5.26 86 37.72 98 (43.0)
EBMT risk score2
0-1 9 3.95 51 22.37 60 (26.3) 0.509†
2 7 3.07 68 29.82 75 (32.9)
3 6 2.63 65 28.51 71 (31.1)
4-6 3 1.32 19 8.33 22 (9.7)
1High risk/low risk genotype group: For definitions see Statistical Analysis section. 2EBMT risk score. For definition see Gratwohl et al.3 *chi squared test; †linear-by-linear associa-
tion (Mantel-Haenszel chi-square); ‡2 sample t test; §Exact significance is reported providing a reliable result regardless of the size, distribution, sparseness, or balance of the
data. 
tive of increased levels of soluble TNFRII in the serum and
decreased TNF.17 With regards to IL10, higher IL-10 secre-
tion has been demonstrated in subjects with the -1082G
allele or GCC haplotype, lower levels with the -1082A
allele and ATA haplotype, and intermediate levels in those
with the ACC haplotype. These haplotypes are defined
by three SNP within the promoter region of the IL-10:
–1082 (G/A), -819 (C/T), and -592 (C/A).20,31,32 The pres-
ence of IL1RN (allele 2) in the donor has been associated
with a reduced incidence of acute GVHD (grades II-IV)
and protection from chronic GVHD and reflects the
down-regulation of IL-1 by IL-1 receptor antagonist.11
These biological effects render it likely that the effects
identified in this study do indeed reflect activity of these
genetic polymorphisms.
Results so far from other groups have been inconsistent,
probably reflecting the heterogeneity of the transplant
cohorts under study. The IL10 ATA/ACC haplotype (low
to intermediate IL-10 producer) was the least frequent
within the present cohort, occurring in 28/228 (12%) of
donors tested. The absence of the IL10 ATA/ACC haplo-
type (or conversely, the presence of ACC/ACC,
ACC/GCC, ATA/ATA, ATA/GCC, or GCC/GCC) in the
remaining 88% of donors was always associated with the
EBMT high-risk groups and poor survival. The presence of
the IL10 ATA/ACC haplotype in the recipient has been
associated in a large cohort of HLA-matched sibling trans-
plants with a moderate risk of both GVHD and lowest risk
of death in remission,33 more severe GVHD occurring in
groups without the IL10 ATA haplotype. The study by Lin
et al.33 assessed overall survival, allele frequency and geno-
types at each IL-10 SNP and showed that the risk of death
was lowest in recipients who were homozygous for the
–592A allele. This pattern was confirmed in our cohort
(results not shown) in which the presence of the homozy-
gous AA allele at -592 conferred the lowest hazard ratio
(0.41 compared to that of the group with the CC reference
genotype). With regards to IL-10 production, it is still
debatable whether the GCC haplotype is associated with
higher or lower IL-10 production in comparison to the
ATA haplotype. In this regard, in another study of unrelat-
ed donor transplants, transplant-related mortality was
associated with the higher IL-10 producer GCC haplotype
when present in the donor.34 However the lower producer
allele (IL10-1082A) has also been associated with poor sur-
vival.35 In a study of peripheral blood stem cell HLA-
matched sibling transplants, the presence of IL10 haplo-
types (ACC/ACC versus ATA/ATC versus ATA/ATA i.e.
lower IL-10 production) increased the incidence of chron-
ic GVHD and in a further study subjects with ATA haplo-
types required more prolonged immunosuppression and
were more susceptible to pulmonary aspergillosis,36,37
whereas the ACC haplotype reduced the risk 9-fold. 
What are the consequences of these data which were
primarily derived from patients with CML and HSCT in
the pre-imatinib era? The success of the phase III IRIS trial
of the tyrosine kinase inhibitor, imatinib, in 200338 has led
to a substantial decrease in the use of HSCT for newly
diagnosed CML and HSCT has become a second-line ther-
apy option for patients in whom imatinib treatment has
failed. With the advent of second generation tyrosine
Impact of genomic risk factors on outcome in CML
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Table 2. Details of model containing EBMT risk score and three addi-
tional genotypes. (N=228)
Coefficient P value Hazard Confidence
ratio interval (95%)
EBMT risk score 0.513 <0.0005 1.67 1.38-2.02
Cytokine gene polymorphism
Donor IL10 ATA/ACC -0.842 0.07 0.43 0.17-1.07
Donor ILIRN allele 2 0.894 0.0 01 2.45 1.48-4.05
Patient TNFRSF1B 196 R -0.603 0.01 0.55 0.35-0.87
Figure 1. (A) Survival probability of 228 patients undergoing allo-
geneic HSCT from an HLA identical sibling for CML (Kaplan Meier
curves), log rank test, P<0.0005. Green line corresponds to high risk
SNP profile, N =25. Blue line corresponds to low risk SNP profile,
N=203. Crosses represent censored observations. (B) Cumulative
Incidence of transplant-related mortality and relapse for 228
patients undergoing allogeneic HSCT from an HLA identical sibling
HSCT for CML. Green line corresponds to high risk SNP profile (trans-
plant-relatd mortality). Blue line corresponds to low risk SNP profile
(transplant-relatd mortality). Gray’s test, P<0.0005. Gray line corre-
sponds to high risk SNP profile (relapse). Black line corresponds to
low risk SNP profile (relapse). Gray’s test, P=0.13.
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kinase inhibitors, the timing of HSCT for patients with a
donor has become crucial. It will be essential to balance
the risks and benefits of a transplant against those of sec-
ond-line therapies.39 Integration of cytokine polymor-
phisms into the established EBMT risk score may improve
patient counseling in the new era.40-44 A favorable geno-
type profile may tip the balance towards early HSCT,
even in responders, and an unfavorable profile, towards a
watch and wait strategy.
The EBMT risk score has recently been confirmed to
predict HSCT outcome for all hematologic indications,4
and additional SNP testing could be added to the EBMT
risk score in general. Furthermore, with the increased use
of reduced intensity conditioning regimens,45 additional
SNP testing could be used to decide between standard
conditioning for patients with a low risk for transplant-
related mortality, reduced conditioning for patients with a
high risk for transplant-related mortality, or for delaying
HSCT until progression.46
Additional risk factors have also been clearly estab-
lished, such as cytomegalovirus serostatus of the recipient,
performance score or comorbidity index. Further gene
polymorphisms will continue to be identified and be
assessed for their impact on outcome, such as those
detailed in recent studies on polymorphisms in the trans-
glutaminase gene.47 It remains difficult to test the impact
of genetic variations in such heterogeneous HSCT patient
populations with traditional multivariable statistical meth-
ods. We propose the novel approach from the present
analysis i.e. application of the concordance index, predic-
tion error and the likelihood ratio test to give evidence
that genetic predictors do improve the goodness of fit and
predictive ability when added to a model consisting of the
EBMT risk score alone. Increasing the goodness of fit in
other situations, such as in cohorts of matched unrelated
donors, would be a strong argument for further utilization
of this novel approach. We also recognize the need for val-
idation in a volunteer donor population.
In conclusion, a few well-defined donor or recipient
cytokine polymorphisms affect outcome after HSCT, and
a statistical technique has been described to verify poten-
tial new genomic risk factors. The approach will refine
risk assessment in order to improve future therapeutic
protocols on an individual patient basis.
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